samples in a patient with PIE syndrome. Interleukin-5 ...

Interleukin-5 levels of pleural fluid and serum samples in a patient with PIE syndrome. R Matsumoto, M Ando, H Kohrogi, S Araki and K Takatsu Chest 1992;102;1296-1297 DOI 10.1378/chest.102.4.1296 The online version of this article, along with updated information and services can be found online on the World Wide Web at: http://chestjournal.chestpubs.org/content/102/4/1296

Chest is the official journal of the American College of Chest Physicians. It has been published monthly since 1935. Copyright1992by the American College of Chest Physicians, 3300 Dundee Road, Northbrook, IL 60062. All rights reserved. No part of this article or PDF may be reproduced or distributed without the prior written permission of the copyright holder. (http://chestjournal.chestpubs.org/site/misc/reprints.xhtml) ISSN:0012-3692

Downloaded from chestjournal.chestpubs.org at COMMAX GROUP on July 10, 2011 © 1992 American College of Chest Physicians

needed,

we

possible,

should

should

think

that

be

make

valve

tried,

valve

reconstruction,

even

iflater

replacement

on

whenever

valve

An

unavoidable.

ciency.

J

Am

Cardiol

J.

2 Eskilsson

JP, 1973;

Tricuspid

SE Traumatic

tricuspid

insufficiency

caused

by

Ann

trauma.

Thorac

Surg

1991;

course

ofsevere

valve

insufficiency

anteroseptal myocardial infarction, coronary tricular septal defect as a result of blunt chest 1989;

with

fistula,

and

yen-

injury.

Z Kardiol

insufficiency:

a clinical

8 Stephenson

LW,

Mac

nonpenetrating

Vaugh

rupture

and

incompetence

H III,

HJ.

Traumatic

1982;

trauma.

Cardiol

1970;

10 Brandenburg Traumatic valve.

J

Cardiol

1966;

Justice J, Olsen patients with suspected 1990; 50:530-33 ML.

Trauma 13

RC,

by 77:

ofblunt

chest A,

Piwnica

tricuspide. vase

monitoring

injury.

Thorac

of myocardial

Ann

contusion:

trauma.

tricuspid

A,

MB,

Miller

FA.

1986; 26:510-20

J,

reconstructive

Soyer

R,

operation

J

evalu-

Cardiovasc

Cardiol

1972;

W, K#{246}rferR. Traumatic Surg

1978;

incompetence.

J

Cardio-

19:557-61

Hirotsugu

Kishi *Fmm

Ando, (Drs.

Kohrogi,

Takatsu, the First

of Pleural Fluid in a Patient

M.D., Ph.D.; Masayuki M.D.; Shukuro Araki, Ph.D. Department

ofinternal

Medicine

M.D. , FC.C.P;

(Drs.

IL-5

that

be

determined

humans,

serum

infection

IL-5.

can

and

have

eosino-

parasite

of

others

IL-5

we

samples

examined

and

pleural

syndrome. AND

were

normal

with

obtained

and

centrifuged

cells

at - 20#{176}C until

with

fluid

was

five

other

from

showed

PIE

The and

pleural

debris.

syndrome

obtained

from

patients

no eosinophilia

effusion.

remove

a patient

Pleural

syndrome who

to

from

volunteers.

PIE

METHODS

Fluid.c

carcinomatous pleurisy eral blood or pleural

in their fluid

These

test

a

with periph-

samples

were

samples

were

use.

Reagents human

with

IL-2,

human

from Genzyme

TB13,

react

IL-i,

Recombinant

more,

human

IL-5

IL-S,5

IL-S.

IL-3,

IL-6

was

and

M-CSF

Mass).

Further-

antibody

as previously

were

and

(Boston,

monoclonal

psorified

TGF-3

C-CSF

IL-4,

Corporation

an anti-mouse

Assay

For the method

to Detect

assay

coated

mM

NaCl,

which

can

described.6

Matsumoto,

IL-5 IL-5,

to detect

with pH

TB13

7.4)

with at

Human

of human

established

were

(5 g/ml)

overnight

PBS

room

we

mouse

slightly

modified

IL-5.3

Briefly,

in PBS

(10

containing

2 percent

temperature.

After

Labs,

polyclonal

rabbit

incubated

again

and

peroxidase-coupled

Richmond,

room

Cal)

was

temperature.

propionic

acid

percent

H202

added

reactions

percent

rIL-S binant

were 320

Figure

nm)

the

by adding

IL-3,

The

lnterteukin-6

test samples at 4#{176}C. Then,

were after

IgG

percent

(10 mM,

10 h at room

(Bio-Rad incubation

3-(4-hydroxy

pH

7.0)

I 0.03

temperature.

NaOH

containing

1.5

measured

at

nm

spectrometer of this

fluorescence

Levels

Ig

was curve

IL-6,

antibodies

0.25N

fluorescence

IL-4,

PBS

IL-S

0.5

buffer

incubated

a standard

2 pg/mI). IL-2,

and

for

with

by an hour’s

washing,

on a fluorescence

1 shows

(sensitivity: IL-i,

stopped

and

NaN3,

(excitation chi).

was

albumin

wells

anti-rabbit

followed

in phosphate

140 were

at 4#{176}C.

goat

added,

After

phenyl) The

anti-human overnight

plates sites

serum the

again,

ELISA

phosphate, binding

bovine

washing

were added

mM

washing

0.05 percent Tween 20 (PBS-Tween), to the wells and incubated overnight

the

polystylen

at 4#{176}C. Nonspecific

applied

containing

at

and

Kohrogi and Araki) and Institute for Medical Immunology Matsumoto and Takatsu), Kumamoto University Medical School, Kumamoto, Japan. Reprint requests: Dr Matswnoto, 1st Department of Internal Medicine, Kumamoto University Medical School, 1-1-1 Honjo, Kumamoto 860, Japan 1296

ten

Horseradish

Ando, M.D.;

PIE

and Pleural

samples

from

2 h

R!,*7ji Matsumoto,

or

in the

eosinophil and

expressing

allergy of

MATERIALS

blocked

lnterleukin-5 Levels and Serum Samples with PIE Syndrome*

We

Surg

25:555-59

mitral

shows

suggest

in mice3

with

factor,

production

of IL-5

Samples

ELISA

Esp

102:1296-97)

humans.2

reports

concentration

patient

araalyzed. P,

y permanente: la insuficiencia

de

a

in

acid

mice

with

method

were obtained Blondeau

for correction

J Thorac

insufficiency.

La anuloplastia selectiva,regulable original para del tratamiento

Rev

the

ofa

stored

Surg

Objective

Dauptain

transgenic

patients

concentration

patient

of

a review

J Trauma

in

These

in some

Recombinant

Deloche

and

teenica

Bircks

RL. Selective

cardiac

that

eosinophilia.’

Serum

L, Giuliani ER. of the tricuspid

61:1-5

15 De Vega NG.

16

blunt

P. Farnell

A, et al. A new

of mitral

una

WR, Prager

1992;

ribonucleic

activity

observed

Serum

insufficiency.

18:911-15

spectrum

Mucha

Carpentier

1971;

Campeau tendineae

is

especially

valvular

caused 1979;

1985; 25:620-27

Frazee

ation 14

The

tricuspid

results

syndrome

of IL-5,

a T-cell-replacing

an ELISA

and

McGoon DC, of the chordae

11 ReifJ,

12 Tenzer

CS. Traumatic

messenger

colony-stimulating

the

26:200-04

RO, rupture

Am

nterleukin-5,’

fluid

Tricuspid

mRNA

Because

71:50-3

KastorJA.

PIE

production

may be due to an enhanced

768-72

J

I

philia

tricuspid

of the ventricular septum J Thorac Cardiovasc Surg

9 Liu SM, Sako Y, Alexander Am

eosinophilia;

with H , Hauch study. Z Kardiol

the

(Che8t

severe

L, Pearson AC. Delayed rupture of tricuspid following blunt chest trauma. Am Heart J 1990; V, Oelert

in

of increased

recently

78:343-47

6 Hilton T, Mezei papillary muscle 119:1410-12 7 Voss H , Petersen

eosinophilia

and serum

These

immunosorbent assay; IHES idiopathic hypereosinophilic syndrome; 1L interleukin; PBS phosphate-buffered saline; PIE pulmonary infiltration with

51:320-22

tricuspid

improved

undetectable.

of a

therapy,

ELISAenzyme-linked

4 Dodd DA, Johns JA, Graham TP Jr. Transient severe mitral and tricuspid regurgitation following blunt chest trauma. Am Heart J 1987; 114:652-54 5 Renner U, Busch UW, Sebening H, Bibra H von, Bauer R. Asymptomatic

(53 pg/mI) steroid

eosinophilia

the lung.

nonpenetrating

chest trauma. Acta Med Scand 1985; 218:347-52 3 Noera G, Sanguinetti M, Pensa P. Biagi B, Cremonesi A, Lodi R, et al. Tricuspid valve incompetence caused by nonpenetrating thoracic

that

in the pleural

samples

Following

became

consequence

32:723-26

serum

syndrome.

concentration

suggested

insuffi-

PIE

was detected

IL-5

in the

fluid disappeared,

IL-5

Nolan

of

and

with

pleural RF, Schrank

ng/ml)

patient

REFERENCES

1 Marvin

production

increased

fluid (7.2

deterioration

G-CSF,

of Pleural


405

(F-3000, ELISA of 2 ng/ml GM-CSF

assay

Hitausing

of recomor

Fluid (Matsumoto

TGF-3

et a!)

Recently, 400

the

Samoszuk

cytoplasm

ophilia

E

in

Hodgkin’s

production.

300

C

ease,

C)

C.) C

of

which

assay

we

C) U)

or

parasites,

0) 0

hyperproduction immune

U-

100

I

I

I

Standard 1. A standard

FIGURE

IL-S

ELISA

was

IL-5

curve

100 at 405

asthma

since

stridor.

During

ofIL-S

high

phils

three in

chest

Also,

with

asthma

with

the

steroid

with human

was

allergy

the

and

number

normal range. As shown in Table 1 , we detected before steroid therapy (53 pg/mI) and

on the

that

but

not

in the

senim

pleural

fluid

showed

no eosinophilia

of other

finding

that

IL-5

factor

sample

was

induced

the

and

IL-5 in

after

serum

pleural

fluid

the

therapy

with

carcinomatous

peripheral

blood

IL-5

has

in the

is important

in humans

Concentration

in

back

to

Pleural

FEUI4S*

Samples serum

(n

=

CJ,

biology

of eosinophil

sample (7.2

effects

ng/

nor

in the

pleurisy

who

or plenaral

as well

serum

(before

Patient’s

serum

(after

Patient’s

pleural

Other

patient’s

steroid

therapy)

53 pg/mI

therapy)

fluid pleural

and

ND steroid

ND 7.2

fluids

(n

=

5)

=

not detected.

lung

With

the

and

and

steroid

We

therapy,

conclude

of PIE

IL-5

have

effusion serum

and

undetectable.

IL-5

might

pleural

normalized

pathogenesis

ng/mI ND

HD,

Young

1G.

differentiation

mouse

and

A, Takaki

M , et

disIL-5

that

IL-

syndrome.

Molecular

factor

B cells.

5, Koyama

a] . Transgenic

differentiation

and

cellular

(interluekin-5)

Immunol

factor

LA,

gene

J

Strath

transgenic

M,

mice

N, Katoh

mice

production.

Dent

and

Rev 1988;

its

102:29-

5, Matsumoto

expressing (IL-5)

Exp

develop

Med

Mellor

1991;

AL,

expressing

a

B

R, Migita

cell

growth

and

eosinophilia

and

auto-

173:429-37

Sanderson

CJ.

interleukin

J

5.

Eosinophils

Exp

in

Med

1990;

172:1425-31 S

Mita

et

S,

Hosoya

al.

Y, Kubota

Rapid

interleukin-S

I,

methods (IL-5)

for using

column.

Harada

N,

Kikuchi

Y, et al.

Takahashi

the

T,

Production

anti-murine

characterization

human IL-5

Natl

1989;

M,

Kinashi

Acad

T,

recombinant

antibody-coupled

Method

of murine

Proc

T, Takahashi

Honjo

of

of a monoclonal

factor

II.

T,

Matsumoto

B-cell

growth

Nishihara

purification

J Immunol

the molecular

125:233-41 T,

antibody

T-cell-replacing USA 1987;

Sci

Ohara

J,

useful

in

factor! 84:4581-

55

7 Samoszuk RNA

M , Nansen

philia. 8 Owen D,

L.

in Reed-Sternberg Blood WF, Sheffer

eosinophils *ND

the

blood

eosinophilia.

the

The

50

defined.’

Concentration

10)

Patient’s

to

to the peripheral

Campbell

on human

3 Tominaga

effusion.

Samples

IL-S

inflammation.

102:107-135 2 Sanderson

is a T-cell-replacing

Serum

that

K, Tominaga A, Harada N, Mita 5, Matsumoto M, T, et al. T cell-replacing factor (TRF)/interleukin 5 (IL5): molecular and functional properties. Immunol Rev 1988;

colony-stimulating

is not

in the

suggested

Takahashi

6

Normal

limited

in the

detected

was

REFERENCES

antibody

IL-5

eosino-

than

ACKNOWLEDGMENTS: We thank Drs. Y. Hirai, M. Takaoki, T. Kishimoto and T Ishii for providing IL-i, IL-2, IL-6 and TGF-, respectively. We also thank Dr. Y. Hosoya (Olympus Optical Co. Ltd. , Tokyo) for purifying polyclonal rabbit anti-human IL-5 IgG antibodies.

4

eosinophil

Although

became

5

effusion fell

in the

steroid

concentration

With

pleural

of eosinophils

in the

its role

1 -1L-5

been

lung

peripheral

immunoaflinity

Table

of the

have

the

patient, fluid

1 Takatsu

controlled

32-stimulants.

patients

production.

in mice,

from

were

syndrome

activity in humansa made it important to study the relationship in some diseases between pathogenesis of eosinophilia and

might

leakage

center

this there

eosino-

DISCUSSION

The

the

of

precipitating

the PIE

asthma

and

shadow

the

effusion No

Thus,

bronchial

consolidation

was

therapy.

fungi or any parasite

was observed. The

which

revealed cells.

pleural

focus

and

within the

ml),

was

drugs causes

accumulate

In our

in the

fungi,

the

eosinophils

develops.

marked

with

pneumonia

a consolidation

pleural

total

other

shadow

to steroid

effusion

of theophylline

completely,

chest

migrating

showed

of the

diagnosed.

therapy,

probably

production

bronchial

blood,

and

Candida,

administration

had

responsive

pleural

for 90 percent

from

peripheral

but

of the

no drug

disappeared

the

distribution

to Aspergillus,

found.

she

roentenogram

no segmental

accounted

antibodies

suffered

an abnormal

years,

treatment

Examination

who

contained

past

her

with

side.

was obtained

REPORT

woman

eosinophilia

admission,

left

patient’s lung

more

ELISA

which

Since

lung,

blood. That much more IL-5 pleural fluid than in the serum

peripheral

( pg/mi)

eosinophils.

is the

pneumonia

was

an

response,

immune

eosin-

of IL-5 role of IL-5.

an

the pulmonary consolidation appeared, eosinophilia was

school

the

to antibiotic

shadow

which

a

I

2000

nm.

Japanese

marked

On

I

concentration

CASE A 28-year-old

resistant

I

200

is shown.

below

with

I

20

philia

Through

some antigens, of

response

migrating

and

2

elicit

that

enhanced IL-5 role of IL-5 in

picogram-order of the

in

in situ

an

suggested

in vivo for example

a part

mRNA

using

due to a crucial

IHES.

the

clarify

In PIE syndrome,

200

C)

therefore

with

detect

IL-5

cells

and

patients

can

could

detected

disease was et ale reported

Owen

eosinophilia

0

Nansen7

Reed-Sternberg

technique

hybridization

Lt)

and

of

nophilic

1990;

in the syndrome.

of interleukin-5

of Hodgkin’s

messenger

with

disease

eosino-

75:13-16

Rothenberg AL,

Detection cells ME,

5 and

blood

ofpatients

J

Med

Exp

CHEST

J,

Petersen

et oil. Interleukin

with 1989;

I 102

Weller

PF,

Silberstein

phenotypically the

altered

idiopathic

hyperosi-

170:343-48

I 4 I OCTOBER,


1992

1297

Interleukin-5 levels of pleural fluid and serum samples in a patient with PIE syndrome. R Matsumoto, M Ando, H Kohrogi, S Araki and K Takatsu Chest 1992;102; 1296-1297 DOI 10.1378/chest.102.4.1296 This information is current as of July 10, 2011 Updated Information & Services Updated Information and services can be found at: http://chestjournal.chestpubs.org/content/102/4/1296 Permissions & Licensing Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.chestpubs.org/site/misc/reprints.xhtml Reprints Information about ordering reprints can be found online: http://www.chestpubs.org/site/misc/reprints.xhtml Citation Alerts Receive free e-mail alerts when new articles cite this article. To sign up, select the "Services" link to the right of the online article. Images in PowerPoint format Figures that appear in CHEST articles can be downloaded for teaching purposes in PowerPoint slide format. See any online figure for directions.
